In today's Traders Exclusive update, George Tkaczuk provides an equity market overview and offers up three new potential trading setups. The Russell 2,000 is lagging the major indexes at this juncture, which is important to note because the small caps were the first group to correct and the first group to bottom in September and October. The 1,183 level will be a key pivot area for the Russell 2,000. Leading sectors of the market include medical, semiconductors, certain areas of retail, and transports. Within medical, there are three biotech stocks of note which might have significant upside. A word of caution, in that these stocks currently have no earnings and their valuations are contingent on the approval of blockbuster drugs. Acadia Pharmaceuticals (ACAD) is one with a promising Alzheimer's drug in the pipeline, and the stock is ready to breakout to new highs. $29-30 is a key level to look to accumulate. ZS Pharma (ZSPH) has a drug for hyperkalemia and the $43 level looks to be an entry. Finally, Opthotech (OPHT) is developing a drug for macular degeneration with very favorable results, and the stock is breaking out at the $44-46 level.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Video
Replay:Jim Cramer Explains What You Should Watch When Banks Report Earnings
Jim Cramer weighs in on JPMorgan Chase's earnings, the stocks that he's got his eye on and what he's watching closely in the markets.
Stock Investors Beware -- Inflation Incoming, but Rates Will Stay Low
Tariffs and inflation have a complicated relationship. Here's how that affects your stock portfolio.
Why Investors Interested in ESG Investing Should Consider This ETF
Looking to get into ESG investing? Or just looking to diversify your portfolio? Impact Shares CEO Ethan Powell explains why investors should consider the NAACP Minority Empowerment ETF.